Newsletter registration

By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Your Profits Grow Sky High.

APEIRON Biologics given green light for market approval

Hans Loibner, Apeiron CEO © Apeiron

The development of dinutuximab beta originally began at the Clinical Cancer Research Institute of St. Anna Children’s Hospital in Vienna and was extended to encompass numerous clinical studies throughout Europe and abroad.

In 2011, Apeiron acquired commercial rights to the project, and then led efforts to win market approval in cooperation with academic groups. More than 1,000 patients have been treated up until now. In September 2016, Apeiron EUSA Pharma acquired an exclusive license to the global commercial rights to dinutuximab beta.

The CHMP recommendation issued on March 24, 2017 will be presented to the European Commission by the EMA. The European Commission will issue a formal decision on the approval of dinutuximab beta within the next two months.

Neuroblastoma is the third most frequent malignant tumor afflicting children. The tumors arise from cells of so-called autonomic nervous system. The apparent cause is that cells do not sufficiently mature in their development phase and then begin to reproduce themselves later in an unrestrained manner. About one out of every 5,000 children suffers from this illness. One third of the tumors already occur in children’s first year.

 

About APEIRON Biologics AG

Apeiron is a private biotech company in Vienna, Austria developing innovative projects in the field of immune-oncology..

For more information: www.apeiron-biologics.com

 

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • ESIB 2019

    18. - 20.11.2019, Graz, Austria

  • Business Breakfast

    20.11.2019 / 8:45 - 11:00, London, UK

Austria Map

Find the perfect location for your company

Thanks to its central location, excellent infrastructure and high quality staff, Austria is one of the key locations for ZTE Corporation and HQ for the Eastern Europe Region in general.

ZTE Austria

logo zte
More testimonials

news from the business location Austria

IFG Asota invests EUR 1.3 million in forward-looking fibre production at its Linz facility

The international fibre manufacturer International Fibres Group (IFG) is increasingly relying on its Asota facility in Linz.

Hiring employees from abroad: What you should keep in mind

Companies are more frequently raising their voices to complain that there is a lack of qualified employees in certain areas, for example IT. This comprises an important reason to increasingly look for suitable talents, also abroad. However, there several things to pay attention to in hiring so-called expatriates, in short expats.

More news All blog posts